Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global $6.6 Billion Preclinical CRO Market Analysis 2014-2025 by Service Type, End-use, and Segment Forecasts -

Research and Markets
Posted on: 05 Feb 18

The "Preclinical CRO Market Analysis By Service Type (Bioanalysis & DMPK Studies, Toxicology Testing, Other Preclinical Services), By End-use, And Segment Forecasts, 2014 - 2025" report has been added to's offering.

The global preclinical CRO market is anticipated to reach USD 6.6 billion by 2025.

The market is expected to witness lucrative growth during the forecast period owing to rise in R&D expenditure on early stage development as well as increase in number of drugs in preclinical phase. Hence, increase in outsourcing penetration is further expected to contribute to the growing demand of life science companies for outsourced preclinical services.

Rise in the number of complex drugs entering preclinical trial and growing pressure to curb R&D expenses are expected to contribute to the growing demand for quality CROs, thereby contributing to the market growth. As per Servier Research Institute, issues related to nonclinical toxicology testing results in a 50% failure rate in the early stage development phase. High failure rate in this phase is expected to contribute to the demand for early stage development CROs during the forecast period.

Rise in outsourcing of R&D and growing competency of CROs are expected to further contribute to the growing demand for early stage development CROs by life science companies. CRO's such as Charles River Laboratories and LabCorp specialize in early phase development services. Vendors in emerging countries, such as India and China, provide quick preclinical services at lower costs, which contributes to the outsourcing of R&D.

Key Findings:

  • Toxicology testing held the largest share in the service segment as of 2016 and is expected to dominate over the forecast period. The attrition of drugs due to toxicity is fueling demand for outsourcing of preclinical studies to CROs, which offer end-to-end services, including toxicology testing.
  • Biopharmaceutical companies are the major clients for preclinical vendors and held the highest share in the end-use segment in 2016 and is expected to dominate over the forecast period.
  • Some of the key players in the preclinical CRO market are Charles River Laboratories International, Inc.; Laboratory Corporation of America; Envigo; Eurofins Scientific; PRA Health Science, Inc.; Wuxi AppTec; Medpace, Inc.; Pharmaceutical Product Development, LLC; and Paraxel International Corporation

Key Topics Covered:

Chapter 1. Executive Summary

Chapter 2. Methodology and Scope

Chapter 3. Preclinical CRO Market Variables, Trends & Scope

Chapter 4. Preclinical CRO: Service Estimates & Trend Analysis

Chapter 5. Preclinical CRO: End-Use Estimates & Trend Analysis

Chapter 6. Preclinical CRO: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

  • Envigo Corporation.
  • MPI Research
  • Eurofins Scientific
  • PRA Health Sciences Inc
  • Wuxi AppTec
  • Medpace Inc.
  • Pharmaceutical Product Development (PPD) LLC
  • PARAXEL International Corporation
  • ICON Plc.
  • Laboratory Corporation of America Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 05/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.